{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:13:10Z","timestamp":1781500390002,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T00:00:00Z","timestamp":1533686400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4722-x","type":"journal-article","created":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T08:01:33Z","timestamp":1533715293000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001\u20132010: a retrospective, population based analysis"],"prefix":"10.1186","volume":"18","author":[{"name":"For Oslo Myeloma Center","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4290-7746","authenticated-orcid":false,"given":"Jon-Magnus","family":"Tangen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geir Erland","family":"Tj\u00f8nnfjord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Gulbrandsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gedde-Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Stormorken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla Dao","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik Hellem","family":"Schjesvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,8]]},"reference":[{"issue":"9983","key":"4722_CR1","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Knop S, Bornha\u00fcser M. Multiple myeloma. Lancet. 2015;385(9983):2197\u2013208.","journal-title":"Lancet"},{"issue":"12","key":"4722_CR2","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","volume":"16","author":"Myeloma Trialists\u2019 Collaborative Group","year":"1998","unstructured":"Myeloma Trialists\u2019 Collaborative Group. Combination chemotherapy plus prednisone as treatment for multiple myeloma. An overview of 6.633 patients from 27 randomized trials. J Clin Oncol. 1998;16(12):3832\u201342.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4722_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harrousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335(2):91\u20137.","journal-title":"N Engl J Med"},{"issue":"19","key":"4722_CR4","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High dose chemotherapy with hematopoetic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875\u201383.","journal-title":"N Engl J Med"},{"issue":"4","key":"4722_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1053\/j.seminhematol.2007.08.010","volume":"44","author":"B Bj\u00f6rkstrand","year":"2007","unstructured":"Bj\u00f6rkstrand B, Gahrton G. High dose treatment with autologous stem cell transplantation in multiple myeloma: past, present and future. Semin Hematol. 2007;44(4):227\u201333. Review","journal-title":"Semin Hematol"},{"issue":"1","key":"4722_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1385\/MO:18:1:65","volume":"18","author":"N Gulbrandsen","year":"2001","unstructured":"Gulbrandsen N, Wisl\u00f8ff F, Brinch L, Carlson K, Dahl IM, Gimsing P, et al. Health-related quality of life in multiple myeloma receiving high dose chemotherapy with autologous blood stem- cell support. Med Oncol. 2001;18(1):65\u201377.","journal-title":"Med Oncol"},{"issue":"9","key":"4722_CR7","first-page":"1228","volume":"91","author":"S Lenhoff","year":"2006","unstructured":"Lenhoff S, Hjort M, Turesson I, Westin J, Gimsing P, Wisl\u00f8ff F, et al. Intensive therapy for multiple myeloma in patients younger than 60 years. Long term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica. 2006;91(9):1228\u201333.","journal-title":"Haematologica"},{"issue":"4","key":"4722_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1365-2141.2006.06042.x","volume":"133","author":"S Lenhoff","year":"2006","unstructured":"Lenhoff S, Hjort M, Westin J, Brinch L, B\u00ebckstr\u00f6m B, Carlson K, et al. Nordic myeloma study group. Impact of age on survival of intensive therapy for multiple myeloma: a population based study by the Nordic myeloma study group. Br J Haematol. 2006;133(4):389\u201396.","journal-title":"Br J Haematol"},{"issue":"21","key":"4722_CR9","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, Ayers D, Robertson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565\u201371.","journal-title":"N Engl J Med"},{"issue":"26","key":"4722_CR10","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609\u201317.","journal-title":"N Engl J Med"},{"issue":"13","key":"4722_CR11","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, et al. Combination therapy with lenalidomide plus dexamethasone (rev\/Dex) for newly diagnosed multiple myeloma. Blood. 2005;106(13):4050\u20133.","journal-title":"Blood"},{"issue":"3","key":"4722_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/2040620713480155","volume":"4","author":"AR Mc Curdy","year":"2013","unstructured":"Mc Curdy AR, Lacy MQ. Pomalidomide and its clinical potential for relapsed and refractory multiple myeloma: an update for the hematologist. Ther Adv Hematol. 2013;4(3):211\u20136.","journal-title":"Ther Adv Hematol"},{"key":"4722_CR13","doi-asserted-by":"publisher","unstructured":"Hari P, Mateos M-V, Abounour R, Knop S, Bensinger W, Ludwig H et al. Efficacy and safety of carfilzomid regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOUR outcomes. Leukemia 2017 May 26; \n                    https:\/\/doi.org\/10.1038\/leu.2017.122\n                    \n                  .","DOI":"10.1038\/leu.2017.122"},{"issue":"5","key":"4722_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/ejh.12609","volume":"95","author":"M Gentile","year":"2015","unstructured":"Gentile M, Vigna E, Recchia AG, Morabito L, Mendicino F, Giagnuolo G, Morabito F. Bendamustine in multiple myeloma. Eur J Haematol. 2015;95(5):377\u201388.","journal-title":"Eur J Haematol"},{"issue":"14","key":"4722_CR15","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1200\/JCO.2010.32.5878","volume":"29","author":"P Moreau","year":"2011","unstructured":"Moreau P, Avet-Loiseau H, Harrousseau J-L, Attal M. Current trends in autologous stem-cell transplantation in the area of novel therapies. J Clin Oncol. 2011;29(14):1898\u2013906.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4722_CR16","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1200\/JCO.2009.25.4177","volume":"28","author":"I Turesson","year":"2010","unstructured":"Turesson I, Velez R, Kristinnson SY, Landgren O. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol. 2010;28(5):830\u20134.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4722_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/bjh.12465","volume":"163","author":"S Pozzi","year":"2013","unstructured":"Pozzi S, Marcheselli L, Bari A, Liardo EV, Marcheselli R, Luminari S, et al. Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population- based analysis. Br J Haematol. 2013;163(1):40\u20136.","journal-title":"Br J Haematol"},{"issue":"1","key":"4722_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/cncr.23145","volume":"112","author":"U-H Mellqvist","year":"2008","unstructured":"Mellqvist U-H, Lenhoff S, Johnsen H, Hjort M, Holmberg E, Juliusson G, et al. Nordic myeloma study group. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients in patients with newly diagnosed multiple myeloma. Cancer. 2008;112(1):129\u201335.","journal-title":"Cancer"},{"issue":"23","key":"4722_CR19","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1182\/blood-2012-11-464503","volume":"121","author":"U-H Mellqvist","year":"2013","unstructured":"Mellqvist U-H, Gimsing P, Hjertner O, Lenhoff S, Lane E, Remes K, et al. For the Nordic myeloma study group. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic myeloma study group randomized phase 3 trial. Blood. 2013;121(23):4647\u201354.","journal-title":"Blood"},{"key":"4722_CR20","doi-asserted-by":"publisher","unstructured":"Tangen JM, Tierens A, Caers J, Binsfeld M, Olstad OK, Siebke Tr\u00f8seid A-M, Wang J, Tj\u00f8nnfjord GE, Hetland G. Immunomodualtory effect of the Agaricus blazei Murill- based mushroom extract Andosan in patients with multiple myeloma undergoing high dose chemotherapy and autologous stem cell transplantation: a randomized, double blinded clinical study. Biomed Res Int 2015. \n                    https:\/\/doi.org\/10.1155\/2015\/718539\n                    \n                  .","DOI":"10.1155\/2015\/718539"},{"issue":"1","key":"4722_CR21","first-page":"7","volume":"95","author":"S Lenhoff","year":"2000","unstructured":"Lenhoff S, Hjort M, Holmbeg E, Turesson I, Westin J, Nielsen JI, et al. Impact on survival of high dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population based study. Nordic Myeloma Study Group Blood. 2000;95(1):7\u201311.","journal-title":"Nordic Myeloma Study Group Blood"},{"issue":"3","key":"4722_CR22","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Cancer. 1975;36(3):842\u201354.","journal-title":"Cancer"},{"issue":"15","key":"4722_CR23","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"P Greipp","year":"2005","unstructured":"Greipp P, San Miguel J, Durie GMB, Crowley JJ, Barlogie B, Blad\u00e9 J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412\u201320.","journal-title":"J Clin Oncol"},{"issue":"7","key":"4722_CR24","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.3324\/haematol.2013.098608","volume":"99","author":"M-L Cretien","year":"2014","unstructured":"Cretien M-L, Hebraud B, Cances-Lauwers V, Hulin C, Marit G, Leleu X, et al. Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high dose melohalan: The IFM experience on 2316 patients. Haematologica. 2014;99(7):1236\u20138.","journal-title":"Haematologica"},{"issue":"3","key":"4722_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000463534","volume":"137","author":"GB Thoenissen","year":"2017","unstructured":"Thoenissen GB, G\u00f6rlich D, Bacher U, Aufenberg T, H\u00fcsken A-C, Hansmeier AA, et al. Autologous stem cell transplantation in multiple myeloma in the era of novel drug induction: a retrospective single center analysis. Acta Haematol. 2017;137(3):163\u201372.","journal-title":"Acta Haematol"},{"key":"4722_CR26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S0037-1963(01)90014-9","volume":"38","author":"M Attal","year":"2001","unstructured":"Attal M, Haroousseau JL. Randomized trial experience of the Intergroupe francophone du myeloma. Sem Hematol. 2001;38:226\u201330.","journal-title":"Sem Hematol"},{"issue":"5","key":"4722_CR27","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.12685","volume":"164","author":"J Liwing","year":"2014","unstructured":"Liwing J, Utterwall K, Lund J, Aldrin A, Blimark C, Carlson K, et al. Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population. Br J Haematol. 2014;164(5):684\u201393.","journal-title":"Br J Haematol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4722-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4722-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4722-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T19:06:36Z","timestamp":1565204796000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4722-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,8]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4722"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4722-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,8]]},"assertion":[{"value":"1 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The search in the patient administrative system, compiling of the clinical data and their subsequent statistical analysis were approved by the Data Protection Officer at Oslo University Hospital, with reference to the Norwegian Patient Record Act \u00a7 6, cf. the Health Personel Act \u00a726. In short, these acts state that a Norwegian health institution may create internal patient databases for quality control of the treatment, provided that specific guidelines to assure the security of the data are followed. For the creation of such databases patient consent or consent from the Ethical Comitee is not required. The data may be subject to publication if completely anonymized.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"801"}}